Molecular Partners (Switzerland) Insiders
| MOLN Stock | CHF 5.20 0.10 1.96% |
Molecular Partners employs about 163 people. The company is managed by 10 executives with a total tenure of roughly 381 years, averaging almost 38.0 years of service per executive, having 16.3 employees per reported executive. Recap of Molecular Partners' management performance can provide insight into the venture performance.
| Daniel Steiner Insider VP Research |
| , MBA Insider Chief Board |
Molecular |
Molecular Partners Management Team Effectiveness
The company has return on total asset (ROA) of 0.3163 % which means that it generated a profit of $0.3163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6246 %, meaning that it generated $0.6246 on every $100 dollars invested by stockholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities.Molecular Partners Workforce Comparison
Molecular Partners AG is regarded second in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 462. Molecular Partners totals roughly 163 in number of employees claiming about 35% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.62 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.61 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.61. Molecular Partners Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Molecular Partners Price Series Summation is a cross summation of Molecular Partners price series and its benchmark/peer.
Molecular Partners Notable Stakeholders
A Molecular Partners stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Molecular Partners often face trade-offs trying to please all of them. Molecular Partners' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Molecular Partners' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel Steiner | VP Research | Profile | |
| Thomas Schwerzmann | VP HR | Profile | |
| Michael Stumpp | Ex CoFounder | Profile | |
| Andreas EMBA | Advisor | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Seth Lewis | Communications Relations | Profile | |
| Patrick Amstutz | CEO, CoFounder | Profile | |
| Renate Gloggner | Ex Board | Profile | |
| Michael Pitzner | Compliance Counsel | Profile |
About Molecular Partners Management Performance
The success or failure of an entity such as Molecular Partners often depends on how effective the management is. Molecular Partners management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Molecular management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Molecular management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people.
Please note, the imprecision that can be found in Molecular Partners' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Molecular Partners AG. Check Molecular Partners' Beneish M Score to see the likelihood of Molecular Partners' management manipulating its earnings.
Molecular Partners Workforce Analysis
Traditionally, organizations such as Molecular Partners use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Molecular Partners within its industry.Molecular Partners Manpower Efficiency
Return on Molecular Partners Manpower
| Revenue Per Employee | 57.2K | |
| Revenue Per Executive | 933K | |
| Net Loss Per Employee | 391.3K | |
| Net Loss Per Executive | 6.4M |
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.